IL280664A - 2-ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיב - Google Patents
2-ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיבInfo
- Publication number
- IL280664A IL280664A IL280664A IL28066421A IL280664A IL 280664 A IL280664 A IL 280664A IL 280664 A IL280664 A IL 280664A IL 28066421 A IL28066421 A IL 28066421A IL 280664 A IL280664 A IL 280664A
- Authority
- IL
- Israel
- Prior art keywords
- arylbenzimidazoles
- ppargc1a
- agonists
- treatment
- neurodegenerative diseases
- Prior art date
Links
- 101150104557 Ppargc1a gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714962P | 2018-08-06 | 2018-08-06 | |
| PCT/US2019/045229 WO2020033359A1 (en) | 2018-08-06 | 2019-08-06 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL280664A true IL280664A (he) | 2021-03-25 |
| IL280664B IL280664B (he) | 2022-12-01 |
| IL280664B2 IL280664B2 (he) | 2023-04-01 |
Family
ID=69413327
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307972A IL307972A (he) | 2018-08-06 | 2019-08-06 | 2-ארילבנזימידאזולים כמריצי pparcg1a לטיפול במחלות ניורודיגנראטיב |
| IL298535A IL298535B2 (he) | 2018-08-06 | 2019-08-06 | 2–ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיב |
| IL280664A IL280664B2 (he) | 2018-08-06 | 2019-08-06 | 2–ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיב |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307972A IL307972A (he) | 2018-08-06 | 2019-08-06 | 2-ארילבנזימידאזולים כמריצי pparcg1a לטיפול במחלות ניורודיגנראטיב |
| IL298535A IL298535B2 (he) | 2018-08-06 | 2019-08-06 | 2–ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיב |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12195432B2 (he) |
| EP (1) | EP3833344A4 (he) |
| JP (2) | JP7422737B2 (he) |
| KR (1) | KR20210068399A (he) |
| CN (2) | CN112805000A (he) |
| AU (1) | AU2019319745B2 (he) |
| BR (1) | BR112021002165A2 (he) |
| CA (1) | CA3108773A1 (he) |
| IL (3) | IL307972A (he) |
| MX (2) | MX2021001456A (he) |
| SG (1) | SG11202101285YA (he) |
| WO (1) | WO2020033359A1 (he) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021002165A2 (pt) | 2018-08-06 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação |
| US20230121720A1 (en) * | 2020-03-13 | 2023-04-20 | Biorchestra Co., Ltd. | Diagnostic methods using pcg-1a expression |
| CN112933232A (zh) * | 2021-02-02 | 2021-06-11 | 袁玉佳 | PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用 |
| CN118541152A (zh) * | 2021-11-02 | 2024-08-23 | 特朗奎斯治疗股份有限公司 | 具有循环髓样细胞炎性表型的受试者的选择和治疗 |
| EP4511024A1 (en) * | 2022-04-22 | 2025-02-26 | RDiscovery, LLC | Treatment of diseases associated with reductive stress |
| KR20250144994A (ko) * | 2022-11-18 | 2025-10-13 | 사토시 고조 | Zln-005 및 관련 화합물의 용도 |
| WO2024118936A1 (en) * | 2022-12-02 | 2024-06-06 | Tranquis Therapeutics, Inc. | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE614236A (he) | 1961-03-01 | |||
| FR1569337A (he) * | 1968-06-18 | 1969-05-30 | ||
| US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| GB1584296A (en) | 1976-12-07 | 1981-02-11 | Kanebo Ltd | 2-substituted benzimidazole compounds |
| NZ222495A (en) | 1986-11-21 | 1991-04-26 | Haessle Ab | Benzimidazole derivatives and pharmaceutical compositions |
| DE3830060A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| JPH09169729A (ja) * | 1995-12-19 | 1997-06-30 | Green Cross Corp:The | 非ペプチド型インターロイキン８拮抗剤 |
| JP4373497B2 (ja) * | 1996-06-19 | 2009-11-25 | ローン−プーラン・ロレ・リミテツド | 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用 |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| KR20010100977A (ko) * | 1998-11-03 | 2001-11-14 | 스타르크, 카르크 | 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도 |
| EP1341768A1 (en) * | 2000-12-07 | 2003-09-10 | AstraZeneca AB | Therapeutic benzimidazole compounds |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| CN1976693A (zh) | 2004-05-20 | 2007-06-06 | 斯克里普斯研究所 | 转甲状腺素蛋白的稳定 |
| WO2006009736A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| WO2006122546A1 (de) | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| DK1913009T3 (da) | 2005-07-28 | 2010-08-16 | Intervet Int Bv | Nye benzimidazol(thio)carbamater med antiparasitisk virkning samt syntese heraf |
| EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| EP2097388B1 (en) | 2006-11-15 | 2011-09-07 | High Point Pharmaceuticals, LLC | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| GB0807103D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| WO2010142426A1 (en) * | 2009-06-11 | 2010-12-16 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| WO2011047129A1 (en) | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| AU2010314891A1 (en) * | 2009-11-06 | 2012-06-07 | Vanderbilt University | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| GB201009656D0 (en) * | 2010-06-09 | 2010-07-21 | Univ St Andrews | Carboxylation catalysts |
| JP5083393B2 (ja) | 2010-09-16 | 2012-11-28 | カシオ計算機株式会社 | 画像表示装置及びプログラム |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| WO2012118935A1 (en) | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| CA2869954C (en) * | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| JP2015532650A (ja) * | 2012-09-05 | 2015-11-12 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用 |
| KR101435496B1 (ko) * | 2012-10-22 | 2014-08-28 | 한국과학기술연구원 | 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CN103113307B (zh) * | 2013-02-27 | 2015-08-05 | 南京大学 | 苯并咪唑类化合物及其应用 |
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| US10272070B2 (en) | 2014-10-14 | 2019-04-30 | The Board of Trustees of the Leland Stanford Junio r University | Method for treating neurodegenerative diseases |
| CN104873500A (zh) | 2015-04-29 | 2015-09-02 | 中国人民解放军第四军医大学 | 化合物zln005的用途 |
| CA2984971A1 (en) | 2015-05-11 | 2016-11-17 | Kancera Ab | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| PL3390367T3 (pl) * | 2015-12-15 | 2021-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Sposób zapobiegania zaburzeniom poznawczym związanym z wiekiem i zapaleniu tkanki nerwowej lub ich leczenia |
| US10654814B2 (en) | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| BR112021002165A2 (pt) | 2018-08-06 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação |
-
2019
- 2019-08-06 BR BR112021002165-5A patent/BR112021002165A2/pt not_active Application Discontinuation
- 2019-08-06 IL IL307972A patent/IL307972A/he unknown
- 2019-08-06 CN CN201980065941.4A patent/CN112805000A/zh active Pending
- 2019-08-06 CA CA3108773A patent/CA3108773A1/en active Pending
- 2019-08-06 SG SG11202101285YA patent/SG11202101285YA/en unknown
- 2019-08-06 MX MX2021001456A patent/MX2021001456A/es unknown
- 2019-08-06 KR KR1020217006736A patent/KR20210068399A/ko not_active Ceased
- 2019-08-06 IL IL298535A patent/IL298535B2/he unknown
- 2019-08-06 US US17/266,433 patent/US12195432B2/en active Active
- 2019-08-06 JP JP2021506624A patent/JP7422737B2/ja active Active
- 2019-08-06 EP EP19845943.0A patent/EP3833344A4/en active Pending
- 2019-08-06 CN CN202411199938.0A patent/CN119033775A/zh active Pending
- 2019-08-06 AU AU2019319745A patent/AU2019319745B2/en active Active
- 2019-08-06 IL IL280664A patent/IL280664B2/he unknown
- 2019-08-06 WO PCT/US2019/045229 patent/WO2020033359A1/en not_active Ceased
-
2020
- 2020-05-29 US US16/888,040 patent/US10851066B2/en active Active
- 2020-10-13 US US17/068,985 patent/US11111217B2/en active Active
-
2021
- 2021-02-04 MX MX2023012694A patent/MX2023012694A/es unknown
-
2024
- 2024-01-16 JP JP2024004449A patent/JP2024056694A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202101285YA (en) | 2021-03-30 |
| JP2024056694A (ja) | 2024-04-23 |
| AU2019319745B2 (en) | 2025-06-26 |
| US10851066B2 (en) | 2020-12-01 |
| WO2020033359A1 (en) | 2020-02-13 |
| EP3833344A4 (en) | 2022-07-06 |
| IL298535B2 (he) | 2024-03-01 |
| IL298535B1 (he) | 2023-11-01 |
| KR20210068399A (ko) | 2021-06-09 |
| IL280664B (he) | 2022-12-01 |
| MX2023012694A (es) | 2023-11-21 |
| BR112021002165A2 (pt) | 2021-05-04 |
| CN119033775A (zh) | 2024-11-29 |
| AU2019319745A1 (en) | 2021-03-25 |
| IL298535A (he) | 2023-01-01 |
| US11111217B2 (en) | 2021-09-07 |
| US20200299244A1 (en) | 2020-09-24 |
| IL280664B2 (he) | 2023-04-01 |
| JP7422737B2 (ja) | 2024-01-26 |
| JP2021534099A (ja) | 2021-12-09 |
| TW202019410A (zh) | 2020-06-01 |
| US20210300877A1 (en) | 2021-09-30 |
| EP3833344A1 (en) | 2021-06-16 |
| US12195432B2 (en) | 2025-01-14 |
| CN112805000A (zh) | 2021-05-14 |
| IL307972A (he) | 2023-12-01 |
| US20210061769A1 (en) | 2021-03-04 |
| CA3108773A1 (en) | 2020-02-13 |
| MX2021001456A (es) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3600309T (pt) | Combinações terapêuticas para o tratamento de doenças hepáticas | |
| IL280664A (he) | 2-ארילבנזימידאזולים כמריצי ppargc1a לטיפול במחלות ניורודיגנראטיב | |
| HUE060711T2 (hu) | Makrociklusos vegyületek betegségek kezelésére | |
| EP3448875A4 (en) | Compositions for the treatment of disease | |
| EP3263132C0 (en) | Composition for treating il-6-related diseases | |
| EP3634417C0 (en) | QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | |
| EP3565846A4 (en) | PROTEIN THERAPEUTICS FOR THE TREATMENT OF SENESCENT CELLS | |
| EP3538548A4 (en) | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| LT3416631T (lt) | Terapiniai agentai, skirti neurodegeneracinių ligų gydymui | |
| IL268850A (he) | שילובים של תולדה 4-פירימידינסולפאמיד עם מרכיבים פעילים לטיפול במחלות הקשורות לאנדותלין | |
| IL273705B (he) | תרכובות בנזותיאזול ושיטות לשימוש בהן לטיפול במחלות נוירודגנרטיביות | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| IL272601A (he) | תכשירים רוקחיים לטיפול במצבים אופתלמיים | |
| IL269158A (he) | תכשירים ושיטות לטיפול במחלות דלקתיות | |
| IL282114A (he) | תהליכים להכנת ציקלואוקטנים פונקציונאליים | |
| IL281244A (he) | קומבינציה תרפאוטית לטיפול במחלות כבד | |
| EP3773629A4 (en) | CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| HUE059584T2 (hu) | Gyógyszerészeti készítmény vérszegénység kezelésére | |
| EP3766497A4 (en) | Drug for treating cough | |
| EP3316887A4 (en) | GLS1-INHIBITOR TO TREAT DISEASES | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| EP3347032A4 (en) | TREATMENT OF ASZITES | |
| HUE064253T2 (hu) | Emulziók hüvelyi fertõzések kezelésére | |
| PL3424499T3 (pl) | Kompozycja farmaceutyczna do leczenia bólu neuropatycznego | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION |